Oncoinvent ASA

Report Publication Announcement • Nov 3, 2025

Reminder: Invitation to presentation of Q3 2025 company update on November 4[th], 2025

Reminder: Invitation to presentation of Q3 2025 company update on November 4[th], 2025

Oncoinvent invites for Q3 2025 company update in English on Tuesday 4[th] of

November at 08:30 AM CEST. The presentation will be broadcasted live on

https://channel.royalcast.com/landingpage/hegnarmedia/20251104_9/. There will be

a possibility for Q&A.

About Oncoinvent

Oncoinvent is a clinical-stage biotechnology company developing novel

radiopharmaceutical therapies against cancer. The lead product candidate,

Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting

micro-metastases post-surgery, harnessing the benefits of modern

radiopharmaceuticals without the complexities of biological targeting.

Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical

development program in two indications. Currently two phase 1/2a trials and one

randomized phase 2 trial are ongoing in the US, UK and Europe. Preliminary

clinical efficacy data are highly encouraging, and no serious toxicity or safety

concerns have been reported to date. The Oncoinvent team consists of approx. 30

employees and runs a state-of-the-art manufacturing facility to produce drug

products for clinical trials in Nydalen, Oslo. Oncoinvent is listed on the

Euronext Growth Oslo.

About Radspherin

Radspherin® is an investigational radiopharmaceutical designed for the local

treatment of cancer that has spread to body cavities. It consists of billions of

calcium carbonate microparticles containing the radioactive material radium-224.

The mode of action is the decay of radium-224 emitting alpha-particles, a highly

potent form of ionizing radiation. Radspherin® is investigated in ongoing

clinical studies to treat peritoneal carcinomatoses from ovarian and colorectal

cancer and it is administered intraperitoneally after surgical resection with

removal of all macroscopic tumors.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press

release are forward-looking statements and are not a representation that

Oncoinvent's plans, estimates, or expectations will be achieved. These forward

-looking statements represent Oncoinvent's expectations as of the date of this

press release, and Oncoinvent disclaims any obligation to update the forward

-looking statements. These forward-looking statements are subject to known and

unknown risks and uncertainties that may cause actual results to differ

materially, including with respect to whether the results of clinical or other

studies will support the use of our product offerings, the impact of results of

such studies, our expectations of the reliability, accuracy and performance of

our tests, or of the benefits of our tests and product offerings to patients,

providers and payers.

For further information, please contact:

Øystein Soug, Chief Executive Officer

Email: soug@oncoinvent.com